[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100476358":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":39,"centralContacts":68,"locations":73,"responsibleParty":188,"collaborators":190,"id":193,"slug":194,"hasResults":195,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":39,"eligibilityCriteria":199,"healthyVolunteers":195,"sex":200,"minAge":201,"maxAge":39,"enrollmentInfo":202,"targetDuration":39,"studyType":205,"phases":206,"briefSummary":209,"conditions":210,"keywords":39,"overallStatus":76,"whyStopped":39,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},{"fullName":5,"class":6},"Phanes Therapeutics","INDUSTRY",[8,14,18,27],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","An accelerated titration design will be employed for early dose levels, followed by the standard 3+3 design at higher dose levels.",[13],"Drug: Spevatamig (PT886)",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion","Two dose levels will be explored; the recommended dose for expansion (RDE) from Part A, and another dose level.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Combination Expansion with Chemotherapy","Part C, substudy C1: 2L m\u002Fa GC\u002FGEJ-C patients will receive Spevatamig (PT886) in combination with Paclitaxel.\n\nPart C, substudy C2: 1L m\u002Fa PDAC patients will receive Spevatamig (PT886) in combination with Gemcitabine plus nab-Paclitaxel (Abraxane).\n\nPart C, substudy C3: 1L m\u002Fa PDAC patients will receive Spevatamig (PT886) in combination with Gemcitabine plus FOLFIRINOX\u002FmFFX.\n\nPart C, substudy C4: 2L BTC patients will receive PT886 in combination with SOC chemotherapy mFOLFOX6.",[13,22,23,24,25,26],"Drug: Paclitaxel","Drug: Gemcitabine","Drug: Abraxane","Drug: FOLFOX","Drug: FOLFIRINOX",{"label":28,"type":10,"description":29,"interventionNames":30},"Combination Expansion with KEYTRUDA® (pembrolizumab)","Part D, substudy D3: 2L or 3L m\u002Fa GC\u002FGEJ-C patients will receive Spevatamig (PT886) in combination with KEYTRUDA® (pembrolizumab).\n\nPart D, substudy D4: 1L HER2 negative m\u002Fa GC\u002FGEJ-C patients will receive Spevatamig (PT886) in combination with SOC chemotherapy and KEYTRUDA® (pembrolizumab).",[13,31,25,32],"Drug: KEYTRUDA® (pembrolizumab)","Drug: CAPOX",[34,40,44,48,52,56,60,64],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","Spevatamig (PT886)","Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.",[19,28,9,15],null,{"type":35,"name":41,"description":42,"armGroupLabels":43,"otherNames":39},"Paclitaxel","Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: substudy C1",[19],{"type":35,"name":45,"description":46,"armGroupLabels":47,"otherNames":39},"Gemcitabine","Chemotherapy as a combination partner to Abraxane and Spevatamig (PT886) in Part C: substudy C2",[19],{"type":35,"name":49,"description":50,"armGroupLabels":51,"otherNames":39},"Abraxane","Chemotherapy as a combination partner to Gemcitabine and Spevatamig (PT886) in Part C: substudy C2",[19],{"type":35,"name":53,"description":54,"armGroupLabels":55,"otherNames":39},"KEYTRUDA® (pembrolizumab)","Immune checkpoint inhibitor as a combination partner to Spevatamig (PT886) in Part D.",[28],{"type":35,"name":57,"description":58,"armGroupLabels":59,"otherNames":39},"FOLFOX","Chemotherapy as a combination partner to Spevatamig (PT886) and KEYTRUDA® (pembrolizumab, Part D only)",[19,28],{"type":35,"name":61,"description":62,"armGroupLabels":63,"otherNames":39},"CAPOX","Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886)",[28],{"type":35,"name":65,"description":66,"armGroupLabels":67,"otherNames":39},"FOLFIRINOX","Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: substudy C3",[19],[69],{"name":5,"role":70,"phone":71,"phoneExt":39,"email":72},"CONTACT","858-766-0852","clinical-trials@phanestx.com",[74,88,97,107,117,127,138,148,158,168,178],{"facility":75,"status":76,"city":77,"state":78,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":87,"contacts":39},"City of Hope (City of Hope National Medical Center, City of Hope Medical Center)","RECRUITING","Duarte","California","91010","United States","US",{"type":83,"coordinates":84},"Point",[85,86],-117.97729,34.13945,{"lat":86,"lon":85},{"facility":89,"status":76,"city":90,"state":78,"zip":91,"country":80,"countryCode":81,"cosmosGeoPoint":92,"geoPoint":96,"contacts":39},"USC Norris Comprehensive Cancer Center","Los Angeles","90033",{"type":83,"coordinates":93},[94,95],-118.24368,34.05223,{"lat":95,"lon":94},{"facility":98,"status":76,"city":99,"state":100,"zip":101,"country":80,"countryCode":81,"cosmosGeoPoint":102,"geoPoint":106,"contacts":39},"Sarah Cannon Research Institute (SCRI)","Denver","Colorado","80218",{"type":83,"coordinates":103},[104,105],-104.9847,39.73915,{"lat":105,"lon":104},{"facility":108,"status":76,"city":109,"state":110,"zip":111,"country":80,"countryCode":81,"cosmosGeoPoint":112,"geoPoint":116,"contacts":39},"University of Iowa","Iowa City","Iowa","52242",{"type":83,"coordinates":113},[114,115],-91.53017,41.66113,{"lat":115,"lon":114},{"facility":118,"status":76,"city":119,"state":120,"zip":121,"country":80,"countryCode":81,"cosmosGeoPoint":122,"geoPoint":126,"contacts":39},"Norton Cancer Institute","Louisville","Kentucky","40202",{"type":83,"coordinates":123},[124,125],-85.75941,38.25424,{"lat":125,"lon":124},{"facility":128,"status":129,"city":130,"state":131,"zip":132,"country":80,"countryCode":81,"cosmosGeoPoint":133,"geoPoint":137,"contacts":39},"Dana-Farber Cancer Institute (DFCI)","ACTIVE_NOT_RECRUITING","Boston","Massachusetts","02215",{"type":83,"coordinates":134},[135,136],-71.05977,42.35843,{"lat":136,"lon":135},{"facility":139,"status":76,"city":140,"state":141,"zip":142,"country":80,"countryCode":81,"cosmosGeoPoint":143,"geoPoint":147,"contacts":39},"Duke Cancer Center","Durham","North Carolina","27710",{"type":83,"coordinates":144},[145,146],-78.89862,35.99403,{"lat":146,"lon":145},{"facility":149,"status":76,"city":150,"state":151,"zip":152,"country":80,"countryCode":81,"cosmosGeoPoint":153,"geoPoint":157,"contacts":39},"University of Pittsburgh Medical Center (UPMC)","Pittsburgh","Pennsylvania","15232",{"type":83,"coordinates":154},[155,156],-79.99589,40.44062,{"lat":156,"lon":155},{"facility":159,"status":76,"city":160,"state":161,"zip":162,"country":80,"countryCode":81,"cosmosGeoPoint":163,"geoPoint":167,"contacts":39},"MD Anderson Cancer Center, GI Medical Oncology Dept","Houston","Texas","77030",{"type":83,"coordinates":164},[165,166],-95.36327,29.76328,{"lat":166,"lon":165},{"facility":169,"status":76,"city":170,"state":171,"zip":172,"country":80,"countryCode":81,"cosmosGeoPoint":173,"geoPoint":177,"contacts":39},"NEXT Oncology","Fairfax","Virginia","22031",{"type":83,"coordinates":174},[175,176],-77.30637,38.84622,{"lat":176,"lon":175},{"facility":179,"status":76,"city":180,"state":181,"zip":182,"country":80,"countryCode":81,"cosmosGeoPoint":183,"geoPoint":187,"contacts":39},"University of Wisconsin Carbone Cancer Center - University Hospital","Madison","Wisconsin","53792",{"type":83,"coordinates":184},[185,186],-89.40123,43.07305,{"lat":186,"lon":185},{"type":189,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR",[191],{"name":192,"class":6},"Merck Sharp & Dohme LLC","100476358","phase-1-spevatamig-pt886-as-monotherapy-or-in-combination-with-chemo-andor-ici-for-the-treatment-of-patients-with-advanced-gastric-gastroesophageal-junction-pancreatic-ductal-or-biliary-tract-carcinomas-the-twinpeak-study-100476358",false,"NCT05482893","Spevatamig (PT886) as Monotherapy or in Combination With Chemo and\u002For ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)","A Phase 1\u002F2, Open-Label, Dose Escalation and Expansion Study With PT886 (Spevatamig) Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, and\u002For an Immune ChecKpoint Inhibitor. The TWINPEAK Study","Key Inclusion Criteria\n\n1. 18 years or older and able to sign informed consent and comply with the protocol.\n2. Measurable disease as defined by RECIST V1.1 criteria for solid tumors.\n3. 3\\. Part A and Part B: Histologically or cytologically confirmed unresectable advanced or metastatic solid gastric, gastroesophageal junction (GEJ), biliary tract or pancreatic carcinomas previously treated for advanced (metastatic or unresectable) disease or for which treatment is not available or not tolerated.\n\n   Part C, substudy C1: 2L m\u002Fa GC\u002FGEJ-C patients will receive Spevatamig (PT886) in combination with Paclitaxel. Patients who are HER2 positive are eligible.\n\n   Part C, substudy C2: 1L m\u002Fa PDAC patients will receive Spevatamig (PT886) in combination with Gemcitabine plus nab-Paclitaxel (Abraxane).\n\n   Part C, substudy C3: 1L m\u002Fa PDAC patients will receive Spevatamig (PT886) in combination with Gemcitabine plus FOLFIRINOX\u002FmFFX.\n\n   Part C, substudy C4: Patients with m\u002Fa BTC who have progressed on 1L SOC chemotherapy (GemCis) ± ICI and are eligible for 2L SOC FOLFOX treatment.\n\n   Part D, substudy D3: 2L or 3L m\u002Fa GC\u002FGEJ-C patients will receive Spevatamig (PT886) in combination with KEYTRUDA® (pembrolizumab).\n\n   Part D, substudy D4: 1L HER2 negative m\u002Fa GC\u002FGEJ-C patients will receive Spevatamig (PT886) in combination with SOC chemotherapy and KEYTRUDA® (pembrolizumab).\n4. Able to provide a formalin fixed, paraffin embedded (FFPE) tumor tissue sample (preferably fresh biopsy or if not possible, archival tissue) to be assessed for CLDN18.2 expression and other biomarkers.\n5. ECOG performance status of 0 or 1.\n6. Adequate organ function confirmed at screening and within 72 hours of initiating treatment.\n\nKey Exclusion Criteria\n\nPatients are excluded from the study if any of the following criteria apply:\n\n1. Women who are pregnant or lactating.\n2. Women of child-bearing potential (WOCBP) who do not use adequate birth control.\n3. Has an active autoimmune disease that has required systemic treatment in the past 2 years.\n4. Prior CLDN18.2 or CD47 targeting therapies, or SIRPα (signal regulatory protein alpha) targeting agents.\n\nAdditional inclusion and exclusion criteria will apply.","ALL","18 Years",{"count":203,"type":204},258,"ESTIMATED","INTERVENTIONAL",[207,208],"PHASE1","PHASE2","This is a first-in-human, Phase 1\u002F2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, biliary tract carcinoma (BTC) and pancreatic ductal adenocarcinoma (PDAC).",[211,212,213],"Gastric or Gastroesophageal Junction Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancer (BTC)","2026-07-07",{"date":216,"type":217},"2026-07-09","ACTUAL",{"date":219,"type":217},"2023-03-15",{"date":221,"type":204},"2028-04",{"name":5,"class":6},11]